Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition

Wang,Chuan‑Jiang; Yang,Dong; Luo,Ying‑Wei

doi:10.3892/etm.2015.2515

Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition

Authors:
- Chuan‑Jiang Wang
- Dong Yang
- Ying‑Wei Luo
View Affiliations

Affiliations: Department of Vascular and Thyroid Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: May 22, 2015 https://doi.org/10.3892/etm.2015.2515
Pages: 603-607

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thyroid cancer is a common endocrine malignancy that has rapidly increased in global incidence. Inhibitor of growth 4 (ING4) has been identified in various types of carcinoma; however, to the best of our knowledge, no previous studies have investigated the effects of ING4 on thyroid cancer. In the present study, SW579 thyroid cancer cells were treated with recombinant ING4 protein, and the results confirmed that recombinant ING4 protein was able to reduce the rate of proliferation, increase the rate of apoptosis and inhibit the mobility of SW579 cells. These results were obtained using a colony formation, fluoroscein isothiocyanate/propidium iodide double staining and Transwell assays, respectively. Furthermore, in the western blot analysis assays, ING4 was demonstrated to inhibit the Wnt/β catenin signaling pathway and epithelial to mesenchymal transition (EMT). Therefore, the present study demonstrated the antitumor activities of recombinant ING4 and identified ING4 could inhibit EMT in thyroid cancer cell. However, additional studies are required to confirm these results in other cell types.

View Figures

View References

1	Shiseki M, Nagashima M, Pedeux RM, et al: p29ING4 and p28ING5 bind to p53 and p300 and enhance p53 activity. Cancer Res. 63:2373–2378. 2003.PubMed/NCBI
2	Byron SA, Min E, Thal TS, et al: Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer. PLoS One. 7:e468232012. View Article : Google Scholar : PubMed/NCBI
3	Zeng ZL, Li FJ, Gao F, Sun DS and Yao L: Upregulation of miR-650 is correlated with downregulation of ING4 and progression of hepatocellular carcinoma. J Surg Oncol. 107:105–110. 2013. View Article : Google Scholar : PubMed/NCBI
4	Li M, Jin Y, Sun WJ, et al: Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma. J Pathol. 219:87–95. 2009. View Article : Google Scholar : PubMed/NCBI
5	Lou C, Jiang S, Guo X and Dong XS: ING4 is negatively correlated with microvessel density in colon cancer. Tumour Biol. 33:2357–2364. 2012. View Article : Google Scholar : PubMed/NCBI
6	Wang QS, Li M, Zhang LY, et al: Down-regulation of ING4 is associated with initiation and progression of lung cancer. Histopathology. 57:271–281. 2010. View Article : Google Scholar : PubMed/NCBI
7	Li X, Zhang Q, Cai L, et al: Inhibitor of growth 4 induces apoptosis in human lung adenocarcinoma cell line A549 via Bcl-2 family proteins and mitochondria apoptosis pathway. J Cancer Res Clin Oncol. 135:829–835. 2009. View Article : Google Scholar : PubMed/NCBI
8	Shen JC, Unoki M, Ythier D, et al: Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res. 67:2552–2558. 2007. View Article : Google Scholar : PubMed/NCBI
9	Colla S, Tagliaferri S, Morandi F, et al: The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: Involvement in myeloma-induced angiogenesis. Blood. 110:4464–4475. 2007. View Article : Google Scholar : PubMed/NCBI
10	Li J and Li G: Cell cycle regulator ING4 is a suppressor of melanoma angiogenesis that is regulated by the metastasis suppressor BRMS1. Cancer Res. 70:10445–10453. 2010. View Article : Google Scholar : PubMed/NCBI
11	Kalluri R and Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 112:1776–1784. 2003. View Article : Google Scholar : PubMed/NCBI
12	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
13	Mani SA, Guo W, Liao MJ, et al: The epithelial mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
14	Santisteban M, Reiman JM, Asiedu MK, et al: Immune-induced epithelial to mesenchymal transition n vivo generates breast cancer stem cells. Cancer Res. 69:2887–2895. 2009. View Article : Google Scholar : PubMed/NCBI
15	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
16	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
17	Song GQ and Zhao Y: Different therapeutic effects of distinct KISS1 fragments on breast cancer n vitro and n vivo. Int J Oncol. 43:1219–1227. 2013.PubMed/NCBI
18	Lokman NA, Elder AS, Ricciardelli C and Oehler MK: Chick chorioallantoic membrane (CAM) assay as an n vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. Int J Mol Sci. 13:9959–9970. 2012. View Article : Google Scholar : PubMed/NCBI
19	Apte U, Zeng G, Thompson MD, et al: beta-Catenin is critical for early postnatal liver growth. Am J Physiol Gastrointest Liver Physiol. 292:G1578–G1585. 2007. View Article : Google Scholar : PubMed/NCBI
20	Nejak-Bowen K and Monga SP: Wnt/beta-catenin signaling in hepatic organogenesis. Organogenesis. 4:92–99. 2008. View Article : Google Scholar : PubMed/NCBI
21	Brown AM: Wnt signaling in breast cancer: Have we come full circle? Breast Cancer Res. 3:351–355. 2001. View Article : Google Scholar : PubMed/NCBI
22	Li J and Zhou BP: Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 11:492011. View Article : Google Scholar : PubMed/NCBI